GlassScriptPhysician profile
Awan K Rahman
NPI 1942735758
$9,016.76
in general payments reported to CMS, 2019-2025
23 companies · $5,925 in 2025
The $5,925 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2021: $130 · 2022: $386 · 2023: $285 · 2024: $1,625 · 2025: $5,925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Food and Beverage: $2,727 · Travel and Lodging: $1,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Food and Beverage | $2,727.41 |
| Travel and Lodging | $1,107.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,260.17 | 2025 | |
| Pulmonx Corporation | $1,316.79 | 2024-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Astrazeneca Pharmaceuticals LP | $1,010.13 | 2023-2025 | Airsupra, Fasenra, Breztri |
| Janssen Pharmaceuticals, INC | $665.48 | 2019 | |
| Glaxosmithkline, LLC. | $469.27 | 2023-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.84 | 2022-2025 | Ofev |
| Regeneron Healthcare Solutions, INC. | $185.12 | 2022-2025 | Dupixent |
| United Therapeutics Corporation | $130.48 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.18 | 2023-2025 | Glassia, Entyvio |
| Nestle Healthcare Nutrition INC. | $76.34 | 2022 | |
| Insmed, INC. | $72.86 | 2024-2025 | Brinsupri, Arikayce |
| Ani Pharmaceuticals, INC. | $62.35 | 2024-2025 | Purified Cortrophin Gel |
| Electromed, INC. | $59.95 | 2022 | |
| Genzyme Corporation | $58.79 | 2025 | |
| Grifols USA, LLC | $48.51 | 2024-2025 | Prolastin-C Liquid |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $43.07 | 2025 | |
| Stryker Corporation | $31.16 | 2025 | Sage Self Oral Care |
| Amgen INC. | $28.72 | 2023-2025 | Tezspire |
| Viatris Specialty LLC | $23.44 | 2025 | Yupelri |
| Janssen Biotech, INC. | $20.75 | 2023 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.07 | 2023 | Xifaxan |
| Vifor Pharma, INC. | $18.15 | 2024 | Zemaira |
| Resmed Corp | $15.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Awan Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.